BCG December 5, 2024
Raakhi Agrawal, Satty Chandrashekhar, Leila Hamidou, Ethan Dabbs, and Ken Keen

The end-to-end journey for a patient starting treatment on branded pharmaceutical products is often complex, time consuming, and unpredictable, leading to high levels of dissatisfaction among health care providers (HCPs), patients, and caregivers alike. Biopharma companies have a unique opportunity to leverage new sources of patient data and technology to create more personalized and seamless patient experiences that have the potential to deliver better health outcomes.

The Push Factors

A number of forces are converging that make now the right time for biopharma companies to take a fresh look at where and how they...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
STAT+: DeepSeek signals China’s rising influence in AI — and AI drug development
Is 2025 the Chinese Year of BioPharma?
Inflation Reduction Act Unintended Consequences For Medical Innovation
Building Resilience: CDMO Strategies for Drug Supply Chain Stability
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s

Share This Article